HIPK2 and extrachromosomal histone H2B are separately recruited by Aurora-B for cytokinesis

Laura Monteonofrio1 · Davide Valente1 · Manuela Ferrara2 · Serena Camerini3 · Roberta Miscione2 · Marco Crescenzi3 · Cinzia Rinaldo1,2 · Silvia Soddu1

Received: 14 November 2017 / Revised: 24 January 2018 / Accepted: 5 February 2018 / Published online: 22 March 2018
© The Author(s) 2018. This article is published with open access

Abstract
Cytokinesis, the final phase of cell division, is necessary to form two distinct daughter cells with correct distribution of genomic and cytoplasmic materials. Its failure provokes genetically unstable states, such as tetraploidization and polyploidization, which can contribute to tumorigenesis. Aurora-B kinase controls multiple cytokinetic events, from chromosome condensation to abscission when the midbody is severed. We have previously shown that HIPK2, a kinase involved in DNA damage response and development, localizes at the midbody and contributes to abscission by phosphorylating extrachromosomal histone H2B at Ser14. Of relevance, HIPK2-defective cells do not phosphorylate H2B and do not successfully complete cytokinesis leading to accumulation of binucleated cells, chromosomal instability, and increased tumorigenicity. However, how HIPK2 and H2B are recruited to the midbody during cytokinesis is still unknown. Here, we show that regardless of their direct (H2B) and indirect (HIPK2) binding of chromosomal DNA, both H2B and HIPK2 localize at the midbody independently of nucleic acids. Instead, by using mitotic kinase-specific inhibitors in a spatio-temporal regulated manner, we found that Aurora-B kinase activity is required to recruit both HIPK2 and H2B to the midbody. Molecular characterization showed that Aurora-B directly binds and phosphorylates H2B at Ser32 while indirectly recruits HIPK2 through the central spindle components MgcRacGAP and PRC1. Thus, among different cytokinetic functions, Aurora-B separately recruits HIPK2 and H2B to the midbody and these activities contribute to faithful cytokinesis.

Introduction
Up to one-third of human cancers are likely to originate through unscheduled tetraploidization, a genetically unstable state that can promote aneuploidy and chromosomal instability (CIN). Faithful cytokinesis is required to preserve ploidy and prevent such genetically unstable state [1–3]. Cytokinesis proceeds through different phases starting from specification of the cleavage plane and ingestion of cleavage furrow, progressing to central spindle assembly and subsequent midbody formation, ultimately ending with abscission [4–6]. The right execution of each phase strictly depends on the success of the previous one, thus chemical biology approaches have been developed to spatially and temporally probe the different phases [7].

Aurora-B is a Ser/Thr kinase that in mammals was originally identified as a kinase overexpressed in cancers [8] and required for cytokinesis [9]. Along with key roles in histone H3 phosphorylation, chromosome condensation/alignment, and spindle assembly checkpoint in mitosis,
Aurora-B acts at different steps throughout cytokinesis [10, 11]. In a spatio-temporal manner, Aurora-B promotes the formation of cleavage furrow, central spindle, and midbody by phosphorylation and recruitment of motors and microtubule-associated proteins, including the central spindle components MKLP1 and MgcRacGAP, the Rho GTPase activator ECT2, and the microtubule-bundling protein PRC1 [12–15]. Finally, when lagging chromatin is present at midbody, Aurora-B prevents abscission through activation of the abscission checkpoint [16, 17].

The midbody is a tightly packed antiparallel microtubule bridge that transiently connects the daughter cells at the end of cytokinesis. It serves as a platform to orchestrate cytoskeleton rearrangements, plasma membrane remodeling, and recruitment of the functional complexes needed for abscission. During its formation, several proteins relocate from central spindle to distinct midbody domains [18]. Besides Aurora-B, midbody assembly and function is regulated by the mitotic kinases CDK1, PLK1, and Citron kinase, which are crucial for localization, interaction, and enzymatic activity of several cytokinesis factors [4]. Recently, we have described the contribution of an additional kinase, homeodomain-interacting protein kinase 2 (HIPK2), and its phosphorylation target, the extrachromosomal histone H2B, in the control of midbody abscission and in prevention of tetraploidization and CIN [19, 20].

HIPK2 is a Tyr-regulated Ser/Thr kinase [21, 22] involved in DNA damage response (DDR) and development [23–25]. In interphase, HIPK2 mostly localizes at nuclear speckles [26] and its nuclear activity is relevant for anticancer therapy because it induces p53-dependent and -independent apoptosis in response to cytotoxic drugs [27, 28]. Histones are the nucleosome assembly proteins; however, a few extrachromosomal activities of histones have been described [29, 30]. In cytokinesis, HIPK2 and extrachromosomal histone H2B colocalize at midbody independently of the presence of DNA, such as chromosome bridges, lagging chromatin, or ultra-fine BLM bridges [19]. At midbody, HIPK2 phosphorylates H2B at Ser14 (H2B-S14P) and contributes to abscission [19]. We also showed...
that H2B localizes at midbody independently of HIPK2, but the absence of the kinase results in loss of H2B-S14P, impaired abscission, and accumulation of tetraploid and polyploid cells that contribute to CIN and increased tumorigenicity [19, 20]. Of relevance, the sole expression of a phosphomimetic H2B-S14D mutant in HIPK2-null cells abolishes cytokinesis defects, restores cell division and proliferation [19], and inhibits tumorigenicity [20]. These data show that HIPK2 controls cytokinesis through extra-chromosomal H2B-S14P and this activity is linked to tumorigenicity. However, which are the molecular pathways involved in the recruitment of HIPK2 and H2B to midbody is still unknown.

In this study, we evaluated the possible contribution of RNA and mitotic kinases in the midbody recruitment of HIPK2 and H2B. We found that both proteins are separately recruited through the activity of the same kinase, Aurora-B.

**Results**

### H2B and HIPK2 localize at the midbody independently of RNA

Previous studies have shown that RNA is required for the assembly of protein complexes such as the 53BP1 foci in DDR [31]. Thus, we tested the possibility that H2B and/or HIPK2 midbody localization might depend on the presence of RNA. We first evaluated whether microRNAs might contribute to midbody localization. Double immunofluorescence (IF) for the midbody marker β-tubulin and H2B or HIPK2 [19] were performed on parental HCT116 cells and their DICER-defective derivatives showing decrease amount of microRNAs [32]. No apparent difference was detectable between the two cell types regarding the midbody localization of both H2B and HIPK2 (Fig. 1a), indicating that microRNAs are dispensable for this event.

To assess whether other types of RNAs might be involved, we treated live HeLa cells with RNases adapting the protocol from Francia and colleagues [31] (Supplementary Figure S1a). We treated live cells enriched in anaphase to assess midbody formation and protein localization in the presence of different types of RNases targeting single and double-strand RNA, and RNA/DNA hybrid (Fig. 1b). As H2B and HIPK2 localize at the midbody independently of DNA [19], DNase I treatment was used as negative control together with buffer-treated cells. As assessed by IF, none of these treatments was able to inhibit midbody formation or the midbody localization of H2B (Fig. 1c) and HIPK2 (Supplementary Figure S1b), indicating that RNAs are dispensable for their midbody recruitment.

**Aurora-B kinase activity is required for midbody localization of HIPK2 and H2B**

To further investigate the mechanisms involved in HIPK2 and H2B midbody recruitment, we started with inhibiting two of the master kinases involved in cytokinesis and midbody formation, PLK1 and Aurora-B. To avoid early-stage effects on central spindle formation, PLK1 and Aurora-B were inhibited by BI 2536 and Hesperadin, respectively, in temporally controlled modes [18, 33] (Supplementary Figures S2a-b). In such conditions, the inhibition of Aurora-B impairs the localization of both
HIPK2 and H2B (Fig. 2a), whereas the block of PLK1 does not affect the midbody recruitment of either of the two proteins (Fig. 2b) or their colocalization with Aurora-B (Supplementary Figure S2c). Similar results were obtained with another Aurora-B inhibitor, the ZM-447439 (Supplementary Figure S2d-f) excluding possible unspecific effects of chemical compounds. Thus, although H2B may localize at the midbody independently of HIPK2 [19], these data indicate that midbody recruitment of either proteins requires the same kinase, Aurora-B.

**Aurora-B binds and phosphorylates H2B but not HIPK2**

We previously defined the midbody localization of HIPK2 and H2B-S14P also based on their colocalization with Aurora-B [19]. To evaluate whether these colocalizations and the recruitment activity of Aurora-B depend on its direct interaction with HIPK2 and H2B, we performed in vitro binding assays with purified proteins. We found that recombinant glutathione S-transferase (GST)-Aurora-B directly binds and phosphorylates H2B (Fig. 3a) but not HIPK2 (Fig. 3b).

![Figure 3](image)

**Fig. 3** Aurora-B directly binds and phosphorylates H2B. 

| Input 1/10 | 150 mM NaCl | 250 mM NaCl |
|------------|-------------|-------------|
| GST        | +           | +           | +           |
| GST-Aurora B | +         | -           | +           |
| His-H2B    | -           | +           | +           |
| anti-Aurora B | +         | -           | -           |
| anti-GST   | -           | +           | -           |
| anti-H2B   | -           | -           | +           |

**b**

| Input 1/10 | 150 mM NaCl | 250 mM NaCl |
|------------|-------------|-------------|
| GFP        | +           | -           | -           |
| GFP-HIPK2  | -           | +           | +           |
| His-H2B    | -           | +           | -           |
| anti-GFP   | -           | +           | -           |
| anti-Aurora B | -       | -           | +           |

**c**

| Input 1/10 | 150 mM NaCl | 250 mM NaCl |
|------------|-------------|-------------|
| GST-Aurora B | +         | +           | +           |
| MBP        | +           | -           | -           |
| His-H2B    | -           | +           | -           |
| GST-HIPK2 K228R | -   | +           | +           |

In vitro kinase assays were performed with GST-Aurora-B, as enzymatic source, and His-H2B or GST-HIPK2-K228R as substrates. Myelin basic protein (MBP) was used as positive control. Proteins were separated by SDSPAGE and radioactivity detected by autoradiography. Coomassie stain was performed as loading control. n = three independent experiment. White asterisks mark nonspecific bands.
recruitment of HIPK2 is independent of H2B, further supporting the separate recruitment of the two proteins.

**Aurora-B phosphorylates H2B at Ser32**

H2B contains nine putative Aurora-B phosphorylation sites. In order to identify specific phosphorylation site/s, we analyzed by mass spectrometry (MS) a recombinant His-H2B protein that had been phosphorylated in vitro by Aurora-B. On a total of 126 amino acids, we were able to properly map the H2B region downstream amino acid 35, where, however, we could not detect any phosphorylated Ser or Thr residues (Supplementary Figure S3a). Unfortunately, the N-terminal region encompassing amino acids 1–35 could not be resolved, despite the employment of several cleavage patterns, probably due to the presence of a high positive charge. Nonetheless, H2B-Ser32 phosphorylation (H2B-Ser32P) has been already reported and a validated anti-p-Histone H2B-S32 Ab is commercially available [34]. Immunoblot analyses of cold kinase assays performed with recombinant His-H2B and GST-Aurora-B

---

**Fig. 4** Aurora-B phosphorylates H2B at Ser32. a Cold in vitro kinase assays were performed and H2B-S32P detected using anti-p-Histone H2B-Ser32 Ab. Ponceau staining and immunoblot with anti-H2B Ab were used as loading controls. n = three independent experiment. b Unsynchronized HeLa cells were treated with Hesperadin or DMSO for 80 min and stained with anti-p-Histone H2B-S32 and anti-β-tubulin Abs. Hoechst was used to stain DNA (blue). Representative images of cells at telophase stage are reported. Scale bar is 5 μm. c Representative confocal images of HeLa cells at indicated stages of mitosis and cytokinesis showing colocalization between H2B-S32P (green) and Aurora-B (red) n = four independent experiment. DNA was stained with Red-Dot2 far-red (pseudo-colored blue); scale bar is 10 μm. d, e HeLa cells stably expressing GFP-H2B WT or its derivative GFP-H2B-S32A at passage two after the establishment of stable populations (i.e., 15 days after blastacidin treatment) were enriched in telophase and protein lysates were obtained from TCEs (T-TCE) or after midbody isolation (MI). Untrasfected HeLa cells were used as negative control. The indicated proteins were analyzed by WB. Immunoblot with anti-PRC1 and anti-p-Histone H2B-S14 Abs were used as positive control to verify the quality of midbody isolation. Immunoblot with anti-PCNA Ab was used as control to evaluate nuclear contamination. Representative WBs are shown. In d, samples were loaded on the same gel and processed on the same filter. Blot was vertically cropped to eliminate non-related samples.
using this Ab showed that Aurora-B is indeed able to phosphorylate H2B-Ser32 in vitro (Fig. 4a).

Next, we verified the specificity of this anti-p-Histone H2B-S32 Ab in IF by using HeLa cells treated with Hesperadin to impair H2B midbody recruitment (Fig. 2a). A clear immunostaining was detected in the midbodies of control cells while no fluorescence was present in Hesperadin-treated cells (Fig. 4b) attesting the specificity of this immunostaining. Therefore, we analyzed the localization of H2B-Ser32P and its relationship with Aurora-B. We found a clear H2B-Ser32P signal already in anaphase A that persists and colocalizes with Aurora-B throughout cytokinesis (Fig. 4c, Supplementary Figure S3b). Of relevance, this phosphorylation was not detectable on nucleosomal H2B belonging to chromosome bridges (Supplementary Figure S3c), supporting a role of extrachromosomal H2B-Ser32 in cytokinesis progression rather than in cytokinesis checkpoint.

Finally, we evaluated whether the Aurora-B-mediated phosphorylation of H2B-Ser32 is essential for H2B midbody recruitment. HeLa cells were transfected with a GFP-tagged wild-type H2B or with a non-phosphorylatable GFP-H2B-S32A mutant form. Similarly to wild-type H2B, the non-phosphorylatable H2B-S32A was present in telophase...
and midbody extracts (Fig. 4d). To exclude a possible contribution from contaminating nucleosomes, immunoblots were reacted with anti-p-Histone H2B-S14 Ab that, in the absence of apoptosis, specifically detects midbody-localized H2B [19] (Supplementary Figure S3d). Also in this condition, the H2B-S32A mutant was detected at midbody (Fig. 4e) indicating that S32 phosphorylation is dispensable for H2B recruitment.

Taken together, these data indicate that Aurora-B phosphorylates H2B at Ser32 and H2B-Ser32 phosphorylation in mitosis follows Aurora-B and persists through cytokinesis. However, these data also indicate that additional Aurora-B-dependent event/s, besides phosphorylation on S32, are required for H2B recruitment.

**HIPK2 is recruited to midbody via Aurora-B-regulated central spindle components**

To get clues on the mechanism of Aurora-B-dependent recruitment of HIPK2 to midbody, we compared the subcellular distribution of HIPK2 full-length (FL) with a series of tag-HIPK2 mutants. Together with HIPK2 deletion forms, we tested a few point mutants including the tumor-associated N958I and R868W mutants, which have been shown to possess a reduced p53 activation capacity [35], the kinase-defective K228R [36, 37], the sumoylation-resistant K32A [38], the ubiquitylation-resistant K1189R [39], and the non-acetylatable K835R [40]. These experiments show that only the region encompassing amino acids 846–1002 of HIPK2, including the speckle retention signal (SRS), is necessary for midbody localization. In contrast, all the other mutants containing this region retain the capacity to localize at midbody (Fig. 5a), although its structure was slightly altered (long, stretched bridges) by overexpression of each HIPK2-carrying vector, suggesting a mild toxic effect independent of the type of mutation.

The SRS region of HIPK2 is required for the physical interactions with many of its targets; [23] thus, we looked for cytokinesis factors that might interact with HIPK2. In order to enrich for cytokinesis factors, total cell extracts (TCEs) were obtained from telophase-synchronized HeLa cells and employed in GST-pull-down assay using purified GST-HIPK2(FL) (Fig. 5b). Such experiment confirmed that Aurora-B does not interact with HIPK2 (Fig. 5c, upper lane). In addition, we observed that abscission proteins (e.g., CEP55, TSG101, ALIX) that reach the midbody later in cytokinesis do not interact with HIPK2 (Fig. 5c, lower lanes). In contrast, MgcRacGAP and PRC1, two key factors in central spindle assembly [13, 14], are reproducibly present in the GST-HIPK2(FL) pull-downs (Fig. 5c, middle lanes) but not in the control GST.

Interestingly, Aurora-B indirectly regulates MgcRacGAP and PRC1 recruitment via their kinesin partners [14, 15]. However, depletion of MgcRacGAP or PRC1, or inhibition of their interaction, has been shown to deeply affect midbody formation [41, 42]. Therefore, to unveil a possible role of MgcRacGAP and/or PRC1 in the midbody recruitment of HIPK2, we followed indirect approaches.

First, we asked whether the HIPK2 region involved in midbody localization is also required for binding to central spindle proteins. As shown by GST-pull-down assays (Fig. 5d), the HIPK2 deletion mutant (1–845), lacking the C-terminal region necessary for midbody recruitment, is actually unable to bind MgcRacGAP and PRC1, suggesting a relationship between midbody localization and interaction with these central spindle factors.

Second, we assessed whether HIPK2 colocalizes with MgcRacGAP and PRC1 at midbody. Double IF analyses of early and late telophase showed that HIPK2 partially colocalizes with the two central spindle factors (Supplementary Figure S4).

Third, we asked whether the Hesperadin-induced inhibition of HIPK2 midbody recruitment is also associated with inhibition of MgcRacGAP and PRC1 midbody
Localization. As shown in Fig. 5e, in the presence of Hesperadin the midbody localization of MgcRacGAP is strongly impaired and that of PRC1 is significantly affected, further supporting a correlation among these events. Thus, we evaluated whether the inhibition of HIPK2 midbody localization is consequent to or concomitant with that of MgcRacGAP and/or PRC1. To this aim, we assessed the midbody localization of the central spindle components upon HIPK2-specific RNA interference. As expected, HIPK2 depletion inhibits H2B-S14P at midbody. However, we could not observe any alteration in the localization of MgcRacGAP, PRC1, and Aurora-B (Fig. 5f), indicating that HIPK2 recruitment temporally follows that of central spindle factors.

Taken together, these results suggest that Aurora-B indirectly recruits HIPK2 to the midbody through MgcRacGAP and PRC1.

**Impairment of Aurora-B-mediated activities on HIPK2 and H2B induces cytokinesis failure**

We previously reported that HIPK2 depletion results in the loss of H2B-S14P at midbody and in the accumulation of binucleated cells due to cytokinesis failure [19]. Analogous readouts are induced by Aurora-B inactivation [43]. Therefore, we asked whether the impairment of Aurora-B-mediated activities on HIPK2 and/or H2B might induce cytokinesis failure.
We inhibited midbody recruitment of the endogenous HIPK2 by sequestering its interactors, McgRacGAP and PRC1. To this aim, HeLa cells were transfected with GFP-HIPK2(791–1196), the minimal C-terminal portion that still localizes at midbody (Fig. 5a), contains the region required to bind McgRacGAP and PRC1, but lacks the kinase domain required to phosphorylate H2B at Ser14 and promote abscission [19]. We cannot directly demonstrate the absence of endogenous HIPK2 at midbody because anti-HIPK2 Abs recognize also the exogenous derivatives. However, we found that compared with HIPK2(FL), HIPK2 (791–1196)-expressing cells have impaired ability to phosphorylate H2B-Ser14 (Fig. 6a) and perform successful cytokinesis, as shown by accumulation of binucleated cells (Fig. 6b).

Next, we assessed whether GFP-H2B-S32A, which cannot be phosphorylated by Aurora-B but can still localize at midbody, has functional consequences on cytokinesis. Compared with wild-type H2B, which does not induce significant effects and can be expressed for extended time, transfection of H2B-S32A resulted in accumulation of binucleated cells in human fibroblasts (HFs; Fig. 6c) and in the loss of H2B-S32A expression after a few passages in HeLa cells (Fig. 6d).

Overall, these results support a role for Aurora-B-mediated activities on HIPK2 and H2B midbody recruitment and in their contribution to faithful cytokinesis.

**Discussion**

HIPK2 works as a haploinsufficient tumor suppressor and its inactivation increases tumorigenicity [44]. The tumor-suppressing activities of HIPK2 have been linked to cell protection against genome instability induced by different types of genotoxic stress, to inhibition of tumor invasion, multidrug resistance, and angiogenesis in hypoxia, and, more recently, to prevention of CIN as consequence of cytokinesis failure. While most of these activities depend on the nuclear functions of HIPK2 [44, 45], prevention of CIN relies, at least in part, on the midbody localization of HIPK2 and its target H2B, and their role in abscission for faithful cytokinesis [19, 20].

In this study, we investigated how HIPK2 and extra-chromosomal histone H2B are recruited to the midbody. Stimulated by the recent observations that microRNAs can be involved in the formation of specific protein complexes [31], we asked whether RNA might be responsible for H2B or HIPK2 cytokinesis recruitment. We tested whether microRNA, single-strand RNA, double-strand RNA, or RNA/DNA hybrid might contribute to midbody recruitment of H2B or HIPK2. However, despite the good quality of our positive controls, we did not observe any defects in H2B or HIPK2 midbody localization, supporting the conclusion that nucleic acids are not involved in the cytokinetic distribution of the kinase and its histone target. Instead, we found that Aurora-B, one of the key mitotic kinases, is needed for the recruitment of both HIPK2 and H2B via two separate mechanisms (Fig. 6e).

Together with PLK1 and CDK1, Aurora-B is a key regulator of cell division. Aurora-B, as a component of the chromosomal passenger complex, localizes to the condensing chromosomes in prophase until the midbody in telophase, passing through the centromeres in metaphase and the central spindle in anaphase [11, 46]. Consistent with its spatio-temporal localization, Aurora-B regulates different mitotic and cytokinetic events promoting or delaying their progression, depending on specific events. Hence, Aurora-B kinase activity promotes chromosome condensation in mitosis and central spindle and midbody formation in cytokinesis. On the other side, Aurora-B inhibits mitosis progression to anaphase until all sister chromatid pairs are properly oriented (i.e., the spindle assembly checkpoint) and prevents abscission in cytokinesis when DNA remains at the cleavage site (i.e., the abscission checkpoint). Here, we found that Aurora-B directly binds and phosphorylates histone H2B at Ser32 in vitro. We observed that H2B-Ser32p colocalizes with Aurora-B at the central spindle in anaphase A and persist throughout the subsequent steps, until abscission. Of relevance, this behavior was detectable at each cytokinesis and was independent from the presence of aberrant DNA at the cleavage plane, thus indicating that H2B-Ser32 phosphorylation by Aurora-B promotes, rather than delays, cell division. In addition, our results indicate that histone H2B is temporally recruited for cytokinesis before HIPK2 and this is consistent with the observation that H2B is present at the midbody also in Hipk2−/− MEFs [19].

As assessed by IF with anti-histone H2B Ab that recognizes the histone independently of its posttranslational modifications, inhibition of Aurora-B kinase activity by Hesperadin or ZM-447439 blocks H2B recruitment. However, the expression of a non-phosphorylatable H2B-S32A mutant showed that Ser32 phosphorylation is dispensable for H2B recruitment because the mutant can still localize at midbody and be phosphorylated at Ser14 by HIPK2. Taken together, these results suggest that other Aurora-B-dependent activities are necessary for the recruitment of H2B. Indeed, based on the complex network of interactions among the microtubule modulators and their regulators during the assembly of the central spindle and midbody [13], this result is not particularly surprising. However, as discussed below, H2B-Ser32p is functionally required for faithful cytokinesis.

We obtained direct and indirect evidence suggesting that HIPK2 is recruited to the midbody through the Aurora-B-
regulated central spindle factors MgcRacGAP and PRC1. Of relevance, during cytokinesis, HIPK2/PRC1 colocalization was previously reported by Hofmann et al. [45]. An important test for the functional significance of these interactions would have been the evaluation of localization epistasis. However, the key role of PRC1 and centralspindlin as hub factors limited our analyses to the evaluation of the proper localization of central spindle factors upon depletion of HIPK2, while the opposite (PRC1 or MgcRacGAP depletion) could not be informative for HIPK2 midbody localization [41, 42]. At this point, we do not know whether there is a direct binding between HIPK2 and central spindle factors. However, we showed that the HIPK2 region required for interaction with MgcRacGAP and PRC1 (the SRS containing region) is also required for midbody localization. Interestingly, the SRS region, besides mediating the interactions with most of the non-homeotic factors, is also involved in the subnuclear localization of HIPK2 into speckled structures [23, 47].

HIPK2 activity and stability are controlled by different posttranslational modifications [48]. We previously showed that the kinase-defective HIPK2-K228R mutant, which is largely hypophosphorylated [21, 22], is still able to localize at the midbody but it is not able to phosphorylate H2B and does not rescue the abscission failure in Hipk2−/− MEFs [19]. Here, we confirmed this observation and extended the analysis to other posttranslational modification-defective mutants, including sumoylation-defective, acetylation-defective, ubiquitylation-resistant, and tumor-associated point mutants. All of these mutants retain the ability to localize at midbody indicating that the posttranslational modifications relevant for HIPK2 activity in stressing conditions are dispensable for the localization at midbody during cytokinesis. Altogether, these results support the conclusion that, in contrast to stressing conditions, the recruitment at midbody of HIPK2 depends on protein/protein interactions rather than posttranslational modifications.

Aurora-B is frequently overexpressed in human cancers and several small molecule inhibitors have been developed and tested in preclinical studies and clinical trials [49, 50]. Consistent with the spatio-temporal localization of Aurora-B, these inhibitors mainly act in mitosis by silencing the spindle assembly checkpoint and leading to chromosome missegregation, cytokinesis failure, and polyploidization [51, 52]. Aurora-B overexpressing tumor cells are particularly sensitive to these effects and eventually undergo cell death. However, proliferating normal cells are also significantly affected resulting in meaningful clinical toxicity [53]. It has been shown that targeting mitotic exit without affecting the spindle assembly checkpoint might have a larger therapeutic window [54]. Yet, such effect cannot be obtained by directly inhibiting the kinase activity of Aurora-B. Thus, a block of the interactions with its cytokinesis partners has been proposed [55]. Here, we show that among different cytokinesis functions, Aurora-B separately recruits HIPK2 and H2B to the midbody and doing so contributes to faithful cytokinesis. Indeed, inhibition of these Aurora-B recruitment activities, by expressing the non-phosphorylatable H2B-S32A mutant or the minimal C-terminal portion of HIPK2 that binds and sequesters MgcRacGAP and PRC1, results in accumulation of binucleated cells. These data confirm a key role for HIPK2 and H2B in cytokinesis and offer the possibility of testing HIPK2 and extrachromosomal histone H2B as therapeutic targets for inhibition of cell division.

Materials and methods

Cell culture and reagents

HeLa (kind gift of C. Passananti), H1299 (kind gift of G. Blandino), U2OS (kind gift of F. Moretti), hTERT-immortalized HF [56], HCT116 parental or DICER-defective (kind gift of B. Vogelstein) were cultured at 37 °C and 5% CO2 in Dulbecco’s modified Eagle’s medium GlutaMAX supplemented with 10% fetal bovine serum, penicillin/streptomycin (Life Technologies). HIPK2-specific RNA interference was performed as described [19]. Kinase inhibitor treatments were performed on unsynchronized, proliferating cells. Hesperadin (Selleckchem) and ZM-447439 (Signalchem) were used to inhibit Aurora-B and Bi 2536 (AbMole) to inhibit PLK1. Solvent dimethylsulfoxide (DMSO; Sigma-Aldrich) was used as control.

Enrichment in telophase, midbody isolation, and RNase treatments

HeLa cells were enriched in telophase by treatment with nocodazole (Sigma-Aldrich; 100 ng/ml for 4 h) followed by mitotic shake-off and nocodazole wash out. Collected cells were plated on poly-L-lysine-coated coverslips and incubated to reach different cytokinesis stages. Midbodies were isolated as described [19, 57] and extracted in buffer (50 mM Tris-HCl pH 7.4, 600 mM NaCl, 0.1% sodium dodecyl sulfate (SDS), 0.5% NP40, 1 mM DTT, 5 mM EDTA) supplemented with protease- and phosphatase-inhibitor mix (Roche).

In vivo RNase A treatment was adapted from Francia et al. [31]. HeLa cells were plated onto poly-L-lysine-coated coverslips and UVB irradiated. One hour later, cells were permeabilized with increasing percentage of Tween20 (0.5,
0.75, 1, 1.5 or 2%) in phosphate-buffered saline (PBS) for 10 min at room temperature (RT). RNase A treatment was carried with 1 mg/ml ribonuclease A from bovine pancreas (Roche) in PBS for 25 min at RT; PBS alone or was used as control. Next, cells were fixed in 2% formaldehyde and immunoreacted with anti-53BP1 Ab (Abcam). Mitotic enriched HeLa cells (45 min post-nocodazole wash out) were permeabilized with 0.75% Tween20 and treated with PBS, RNase A (Roche), RNase III (25U; Ambion), RNase H (25U, Ambion), or DNase I (25U; Ambion), fixed with 2% formaldehyde for 10 min or cold methanol 100% for 5 min at −20 °C.

Western blotting

TCEs were prepared in lysis buffer (50 mM Tris-HCl pH 8.0, 150 mM NaCl, 0.5% sodium-deoxycholate, 0.1% SDS, 1% NP40 and 1 mM EDTA) supplemented with protease inhibitor mix (Roche) and Halt Phosphatase Inhibitor Cocktail (Life Technologies). Proteins were resolved by SDS-polyacrylamide gel electrophoresis (PAGE) using NuPAGE® Novex Bis-Tris Gels (Life Technologies), transferred onto nitrocellulose membranes (Bio-Rad), and analyzed with the required Abs. Horseradish peroxidase (HRP)-conjugated goat anti-mouse and anti-rabbit secondary Abs (Bio-Rad) were used. Immunoreactivity was determined by ECL-chemioluminescence reaction (Amer-sham). The following Abs were employed: anti-TSG101, anti-cep55, anti-MgcRacGAP1, anti-p-histone-H2B-S32, and anti-Aurora-B (Abcam); anti-PRC1, anti-Alix, anti-PCNA, and anti-GST (Santa Cruz); anti-GFP (Roche); anti-p-histone-H2B-S14 (Cell Signaling).

IF microscopy

Cells were seeded onto poly-L-lysine-coated coverslips, fixed in ice-cold methanol or 2% formaldehyde, washed three times in PBS, permeabilized in 0.25% Triton X-100 in PBS for 10 min, blocked in 0.2% Triton X-100, 5% bovine serum albumin in PBS for 60 min before the required primary Abs were applied. The following Abs were employed: anti-Aurora-B (BD-Bioscience); anti-ECT2, anti-PRC1, anti-MKLP1, and anti-PLK1 (Santa Cruz); anti-HIPK2 (rabbit polyclonal Ab [19]); anti-p-histone-H2B-S14 (Cell Signaling); anti-p-histone-H2B-S32, anti-H2B, anti-53BP1, and anti-MgcRacGAP1 (Abcam); anti-β-tubulin-Cy3 and anti-α-tubulin-FITC (Sigma-Aldrich); secondary 488- or 594-conjugated Abs (Life Technologies). DNA was marked with Hoechst 33342 (Sigma-Aldrich) or Red-Dot2 far-red (Biotium). Cells were examined under an Olympus BX53 microscope using a cooled camera device (ProgRes MF) and with confocal microscope Zeiss LSM510-Meta.

Expression vectors and recombinant proteins

The following expression vectors were employed: pEGFP-c2, pEGFP-HIPK2-FL and its derivative deletion and point mutants pEGFP-HIPK2-1-633; pEGFPHIPK2-1-845; pEGFP-HIPK2-delta846-1002; pEGF-PHIPK2-K228R; pEGFP-HIPK2-K1189R [39]; pLucX-HA-HIPK2-R868W and pLucX-HA-HIPK2-N958I [35] kind gift of I. Kitabaiashi; pcDNA3-Flag-HIPK2-K32 and pcDNA3-Flag-HIPK2-K835R [40] kind gift of L.M. Schmidtz, pBOS-GFP-H2B (BD PharMingen). pBOS-GFP-H2B-S32A mutant was obtained by site-directed mutagenesis using QuickChange kit (Stratagene) and analyzed by sequencing. To gain high levels of GST, GST-HIPK2-FL or its derivatives, H1299 cells were infected with vTF7-3 followed by transfection with pcDNA3-eGST, pcDNA3eGST-HIPK2 or its derivatives, as described [22]. Recombinant GFP and GFP-HIPK2 were produced in U2OS cells by transfection of pEGFP-c2 or pEGF-HIPK2, as described [58]. GST-Aurora-B (A2108) and MBP (M1891) are from Sigma-Aldrich, His-H2B (Ag7811) from Proteintech.

GST pull-down and binding assay

GST-fusion proteins were purified from TCEs using Glutathione-Sepharose 4 Fast Flow (GE Healthcare), incubated for 2 h at 4 °C with glutathione sepharose beads, pulled-down, washed three times with nondenaturating lysis buffer, and used as bait in binding assays. For H2B and Aurora-B binding assays, GST-fusion proteins were incubated with 500 ng of recombinant His-H2B (Proteintech) in 50 mM Tris-HCl pH 7.5 at two salt concentrations, 150 and 250 mM NaCl. For T-TCE binding assays, GST-fusion proteins were incubated with 0.6 mg of T-TCE in binding buffer (50 mM Tris-HCl pH 7.5, 200 mM NaCl, 0.5% NP40). For HIPK2 and Aurora-B binding assays, GFP or GFP-HIPK2 were purified as described [58]. TCEs were prepared 24 h post-transfection of U2OS cells. Supernatants obtained after TCE centrifugations were incubated overnight with anti-GFP Ab-sepharose beads (Abcam) at 4 °C. GFP-proteins were incubated with GST-Aurora-B in 50 mM Tris-HCl pH 7.5 at two salt concentrations (150 and 250 mM NaCl). Bound proteins were analyzed by WB.

Kinase assay and mass spectrometry

Kinase assays were performed incubating 150 ng of GST-Aurora-B in kinase buffer (Hepes 20 mM pH 7.5, 1 mM DTT, 10 mM MgCl2 and 1 mM EGTA) in the presence of γ-32P-ATP (Perkin-Elmer, BLU502Z250UC) at 30 °C for 30 min. MBP, His-H2B, or GST-HIPK2-K228R were used as substrates. GST-HIPK2-K228R alone was used to
evaluate the autophosphorylation level of the defective mutant. Proteins were resolved by SDS-PAGE and phosphorylation analyzed by autoradiography.

Cold kinase assays were performed with 2 μM ATP (Roche) for 1 h and phosphorylated H2B analyzed by WB or MS. For MS, H2B was in-gel digested with trypsin, chymotrypsin, AspN or GluC and peptides analyzed by liquid chromatography MS using an Ultimate 3000 HPLC (DIONEX) connected on line with a linear Ion Trap (LTQ, Thermo). MS/MS and MS/MS/MS were acquired in order to search for phosphopeptides carrying mass increase and neutral losses, respectively. Tandem mass spectra were analyzed by Proteome Discoverer software (version 1.4, Thermo Electron) searching.

**Statistics**

All data are presented as mean ±S.D. (standard deviation). The p-values were derived from unpaired two-tailed t-tests using GraphPad Prism software. The p-values < 0.05 were considered significant. In all, 80 midbodies and 1000 cells for each condition were scored, unless otherwise stated.

**Acknowledgements** We are grateful to all people cited in the text for their gifts of cells and reagents. We thank G. Di Rocco for critical reading of the manuscript and F. Magi and M.P. Gentileschi for technical assistance. This work was supported by grants from Italian Association for Cancer Research to SS (IG #14592), and to CR (IG #17739). LM and DV were recipients of fellowships from Italian Foundation for Cancer Research.

**Compliance with ethical standards**

**Conflict of interest** The authors declare that they have no conflict of interest.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

**References**

1. Normand G, King RW. Understanding cytokinesis failure. Ad Exp Med Biol. 2010;676:27–55.
2. Storchova Z, Kuffer C. The consequences of tetraploidy and aneuploidy. J Cell Sci. 2008;121:3859–66.
3. Vitale I, Manic G, Senovilla L, Kroemer G, Galluzzi L. Karotypic aberrations in oncogenesis and cancer therapy. Trends Cancer. 2015;1:124–35.
4. Fededa JP, Gerlich DW. Molecular control of animal cell cytokinesis. Nat Cell Biol. 2012;14:440–7.
5. Mierzwa B, Gerlich DW. Cytokininetic abscission: molecular mechanisms and temporal control. Dev Cell. 2014;31:525–38.
6. Pollard TD. Nine unanswered questions about cytokinesis. J Cell Biol. 2017;216:3007–16.
7. Atilla-Gokcumen GE, Castoreno AB, Sasse S, Eggert US. Making the cut: the chemical biology of cytokinesis. ACS Chem Biol. 2010;15:79–90.
8. Bischoff JR, Anderson L, Zhu Y, Mossie K, Ng L, Souza B, et al. A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J. 1998;17:3052–65.
9. Terada Y, Tatsuka M, Suzuki F, Yasuda Y, Fujita S, Otsu M. AIM-1: a mammalian midbody-associated protein required for cytokinesis. EMBO J. 1998;17:667–76.
10. Goto H, Yasui Y, Nigg EA, Inagaki M. Aurora-B phosphorylates histone H3 at serine28 with regard to the mitotic chromosome condensation. Genes Cells. 2002;7:11–7.
11. Afonso O, Figueiredo AC, Maiato H. Late mitotic functions of Aurora kinases. Chromosoma. 2017;126:93–100.
12. Glotzer M. The molecular requirements for cytokinesis. Science. 2005;307:1735–9.
13. Douglas ME, Mishima M. Still entangled: assembly of the central spindle by multiple microtubule modulators. Semin Cell Dev Biol. 2010;21:899–908.
14. Nunes Bastos R, Gandhi SR, Baron RD, Gruneberg U, Nigg EA, Barr FA. Aurora B suppresses microtubule dynamics and limits central spindle size by locally activating KIF4A. J Cell Biol. 2013;202:605–21.
15. Douglas ME, Davies T, Joseph N, Mishima M, Aurora B and 14-3-3 coordinate the central spindle microtubules. EMBO J. 2014;33:202:13–28.
16. Norden C, Mendoza M, Dobbelaeere J, Kowalskiwe J, Biggs S, Barral Y. The NoCut pathway links completion of cytokinesis to spindle midzone function to prevent chromosome breakage. Cell. 2006;125:85–98.
17. Agromayor M, Martinez-Serrano J. Knowing when to cut and run: mechanisms that control cytokinetic abscission. Trends Cell Biol. 2013;23:433–41.
18. Hu CK, Coughlin M, Mitchison TJ. Midbody assembly and its regulation during cytokinesis. Mol Biol Cell. 2012;23:1024–34.
19. Rinaldo C, Moncada A, Gradi A, Ciuffini L, D’Eliseo D, Siepi F, et al. HIPK2 controls cytokinesis and prevents tetraploidization by phosphorylating histone H2B at the midbody. Mol Cell. 2012;47:87–98.
20. Valente D, Bossi G, Moncada A, Torincasa M, Indelicato S, Piscuoglio S, et al. HIPK2 deficiency causes chromosomal instability by cytokinesis failure and increases tumorigenicity. Oncotarget. 2015;6:10320–34.
21. Saul VV, de la Vega L, Milanovic M, Krüger M, Braun T, Fritz-Wolf K, et al. HIPK2 kinase activity depends on cis-autophosphorylation of its activation loop. J Mol Cell Biol. 2013;5:27–38.
22. Siepi F, Gatti V, Camerini S, Crescenzini M, Soddu S. HIPK2 catalytic activity and subcellular localization are regulated by activation-loop Y354 autophosphorylation. Biochem Biophys Acta. 2013;1833:1443–53.
23. Rinaldo C, Prodosmo A, Siepi F, Soddu S. HIPK2: a multitalented partner for transcription factors in DNA damage response and development. Biochem Cell Biol. 2007;85:411–8.
24. Kuwano Y, Nishida K, Akaite Y, Kurokawa K, Nishikawa T, Masuda K, et al. Homeodomain-interacting protein kinase-2: a
critical regulator of the DNA damage response and the epigene. Int J Mol Sci. 2016;17:E1638.
25. Blaquier JA, Verheyen EM. Homeodomain-interacting protein kinases: diverse and complex roles in development and disease. Curr Top Dev Biol. 2017;123:73–103.
26. Kim YH, Choi CY, Kim Y. Covalent modification of the homeodomain-interacting protein kinase 2 (HIPK2) by the ubiquitin-like protein SUMO-1. Proc Natl Acad Sci USA. 1999;96:12350–5.
27. D’Orazio G, Rinaldo C, Soddu S. Updates on HIPK2: a resourceful oncossuppressor for clearing cancer. J Exp Clin Cancer Res. 2012;31:63.
28. Matt S, Hofmann TG. The DNA damage-induced cell death response: a roadmap to kill cancer cells. Cell Mol Life Sci. 2016;73:2829–50.
29. Konishi A, Shimizu S, Hirota J, Taka0 T, Fan Y, Matsuoka Y, et al. Involvement of histone H1.2 in apoptosis induced by DNA double-strand breaks. Cell. 2003;114:673–88.
30. Kobiya K, Takeshita F, Jouani N, Sakaeu-Sawano A, Miya-waki A, Ishii KJ, et al. Extrachromosomal histone H2B mediates innate antiviral immune responses induced by intracellular double-stranded DNA. J Virol. 2010;84:822–32.
31. Francia S, Michelini F, Saxena A, Tang D, de Hoon M, Anelli V, et al. Site-specific DICER and DROSHA RNA products control the DNA-damage response. Nature. 2012;488:231–5.
32. Cummins JM, He Y, Leary RJ, Pagliarini R, Diaz LA Jr, Sjoblom T, et al. The colorectal microRNAome. Proc Natl Acad Sci USA. 2006;103:3687–92.
33. Hauf S, Cole RW, LaTerra S, Zimmer C, Schnapp G, Walter R, et al. The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore-microtubule attachment and in maintaining the spindle assembly checkpoint. J Cell Biol. 2003;161:281–94.
34. Lau AT, Lee SY, Xu YM, Zheng D, Cho YY, Zhu F, et al. Phosphorylation of histone H2B serine 32 is linked to cell transformation. J Biol Chem. 2011;286:26628–37.
35. Li XL, Aray Y, Harada H, Shima Y, Yoshida H, Rokudai S, et al. Mutations of the HIPK2 gene in acute myeloid leukemia and myelodysplastic syndrome impair AML1- and p53-mediated transcription. Oncogene. 2007;26:7231–9.
36. Hofmann TG, Möller A, Sirma H, Zentgraf H, Taya Y, Dröge W, et al. Regulation of p53 activity by its interaction with homeodomain-interacting protein kinase-2. Nat Cell Biol. 2002;4:11–19.
37. D’Orazio G, Cecchinelli B, Bruno T, Manni I, Higashimoto Y, Saito S, et al. Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser46 and mediates apoptosis. Nat Cell Biol. 2002;4:11–19.
38. Gresko E, Möller A, Rosic A, Schmitz ML. Covalent modification of human homeodomain interacting protein kinase 2 by SUMO-1 at lysine 25 affects its stability. Biochem Biophys Res Commun. 2005;329:1293–9.
39. Rinaldo C, Prodosmo A, Mancini F, Jacovelli S, Sacchi A, Moretti F, et al. MDM2-regulated degradation of HIPK2 prevents p53Ser16phosphorylation and DNA damage-induced apoptosis. Mol Cell. 2007;25:739–50.
40. De la Vega L, Fröbius K, Moreno R, Calzado MA, Geng H, Schmitz ML. Control of nuclear HIPK2 localization and function by a SUMO interaction motif. Biochim Biophys Acta. 2011;1813:283–97.
41. Zhao WM, Fang G. MgcRacGAP controls the assembly of the contractile ring and the initiation of cytokinesis. Proc Natl Acad Sci USA. 2005;102:13158–63.
42. Mollinarini C, Kleman JP, Saoudi Y, Jablonski SA, Perard J, Yen TJ, et al. Ablation of PRC1 by small interfering RNA demonstrates that cytokinetic abscission requires a central spindle bundle in mammalian cells, whereas completion of furrowing does not. Mol Biol Cell. 2005;16:1043–55.
43. Borisa AC, Bhatt HG. A comprehensive review on Aurora kinase: small molecule inhibitors and clinical trial studies. Eur J Med Chem. 2017;140:1–19.
44. Feng Y, Zhou L, Sun X, Li Q. Homeodomain-interacting protein kinase 2 (HIPK2): a promising target for anti-cancer therapies. Oncotarget. 2017;8:20452–61.
45. Hofmann TG, Glas C, Bitomsky N. HIPK2: a tumour suppressor that controls DNA damage-induced cell fate and cytokinesis. Bioessays. 2013;35:55–64.
46. Carmena M, Wheelock M, Funabiki H, Earnshaw WC. The chromosomal passenger complex (CPC): from easy rider to the godfather of mitosis. Nat Rev Mol Cell Biol. 2012;13:789–803.
47. Rinaldo C, Siepi F, Prodosmo A, Soddu S. HIPK2: jack of all trades in basic nuclear activities. Biochim Biophys Acta. 2008;1783:2124–9.
48. Saul VV, Schmitz ML. Posttranslational modifications regulate HIPK2, a driver of proliferative diseases. J Mol Med (Berl). 2013;91:1051–8.
49. Kollareddy D, Zheleva D, Dzubak P, Brahmkshatriya PS, Lepsik M, Hajduch M. Aurora kinase inhibitors: progress towards the clinic. Invest New Drugs. 2012;30:2411–32.
50. Bavetsias V, Linardopoulos S. Aurora kinase inhibitors: current status and outlook. Front Oncol. 2015;5:278.
51. Ditchfield C, Johnson VL, Tigher A, Elliston R, Haworth C, Johnson T, et al. Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores. J Cell Biol. 2003;161:267–80.
52. Carpinelli P, Mell J. Aurora kinase inhibitors: identification and preclinical validation of their biomarkers. Expert Opin Ther Targets. 2008;12:69–80.
53. Lens SM, Voest EE, Medema RH. Shared and separate functions of polo-like kinases and aurora kinases in cancer. Nat Rev Cancer. 2010;10:825–41.
54. Huang HC, Shi J, Orth JD, Mitchison TJ. Evidence that mitotic exit is a better cancer therapeutic target than spindle assembly. Cancer Cell. 2009;16:347–58.
55. D’Avino PP, Capalbo L, New Auroras on the roles of the chromosomal passenger complex in cytokinesis: implications for cancer therapies. Front Oncol. 2015;5:221.
56. Lazzari C, Prodosmo A, Siepi F, Rinaldo C, Galli F, Gentileschi M, et al. HIPK2 phosphorylates ΔNp63α and promotes its degradation in response to DNA damage. Oncogene. 2011;48:402–13.
57. Kuriyama R, Keryer G, Borisy GG. The mitotic spindle of Chinese hamster ovary cells isolated in taxol-containing medium. J Cell Sci. 1984;66:265–75.
58. Verdina A, Di Rocco G, Virdia I, Monteneofri0 L, Gatti V, Policicchio E, et al. HIPK2-T566 autophosphorylation diversely contributes to UV- and doxorubicin-induced HIPK2 activation. Oncotarget. 2017;8:16744–54.